Abstract
Background: The immune checkpoint inhibitors (ICIs) have changed the treatment of non-small cell lung cancer (NSCLC) but there are few predictive and prognostic biomarkers. Even with high levels of PD-L1 expression, some patients do not benefit from anti-PD1 or PD-L1 inhibitors. Neutrophil-to-lymphocyte ratio (NLR) has been shown to be a potential biomarker in these settings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
